The new round of northeast revitalization is in the period of breaking through the barriers. This year2In January, the Central Committee of the Communist Party of China Several Opinions of the State Council on the Comprehensive Revitalization of the Northeast and Other Old Industrial Bases "issued;4In January, the State Council agreed to Shenyang National High-tech Zone and Dalian National High-tech Zone to jointly build Shenyang-Dalian National Independent Innovation Demonstration Zone;7In January, the "Approval of the State Council on the Pilot Program for Promoting Comprehensive Innovation and Reform of the Shenyang System" was officially released. This series of policy releases, decision-making and deployment is not only a mobilization order for the expedition, but also a compass for action.

The northeast will be revitalized again, Shenyang will go first, and Hunnan will be the pioneer. As the Shenyang National High-tech Industrial Development Zone, Hunnan District has vigorously developed high-tech industries in recent years and focused on building a technological innovation engine. It is gradually becoming the birthplace of Shenyang's strategic emerging industries, and continues to cultivate, develop and expand leading enterprises in various emerging industries. Liaoning Chengda Biological Co., Ltd. (referred to as Chengda Biological) is a typical representative of them.

Nowadays, vaccine safety has become the focus of attention of Chinese people, and people pay more and more attention to reliable vaccine products. Trustworthy technical level and reliable management process are the advantages of Chengda Biology. By virtue“International level, domestic leading”The technical level,“Make sure every vaccine is safe.”The management process, into a large biological not only won the favor of the Chinese people, in the world market,“New Third Board”There is also a very eye-catching performance in the capital markets.

　　Fill in the gaps

Drive the Chinese to a new level with rabies vaccine

Once rabies occurs, the mortality rate is as high100%The most effective way to save your life is to inject rabies vaccine in time after being bitten. while in2005Years ago, the rabies vaccine with adjuvant produced by traditional manual technology was still widely used in China, which would not only cause local pain, induration and other adverse reactions, but also slow antibody production could not quickly protect the lives of patients.2005Year4In January, the human rabies vaccine produced by Chengda Bio was successfully launched, which greatly promoted the improvement of national standards and promoted the upgrading of vaccines. That year9Months later, the adjuvant rabies vaccine gradually withdrew from the historical stage, and the quality of rabies vaccine for human use in our country jumped to a new level.

　　2002In 2003, Liaoning Chengda Co., Ltd. and Liaoning Biomedical Engineering Research Institute took root in Hunnan District and jointly established Chengda Biology to look at the world and enter the vaccine market. introduced from abroad“Bioreactor large-scale cell culture vaccine production technology”After that, on the basis of digestion and absorption, Chengda Biology has formed a core technology with independent intellectual property rights through independent innovation.-"Process platform technology for large-scale vaccine preparation in bioreactor”It has overcome the technical problem of large-scale cell culture to prepare high-quality vaccines in China for more than ten years, filled the domestic gap in vaccine production technology, reached the international advanced level, and broke the long-term monopoly of multinational companies in China's high-end human rabies vaccine.

After14With the development of the year, Chengda Bio has become a leader in the domestic human rabies vaccine industry. Whether it is production technology, product quality, market share, business performance or corporate image, it is in a leading position in the industry. The company's production plant in Hunnan District covers an area of nearly 100 acres, building area5More than 10,000 square meters, near employees800People. There is a rabies vaccine workshop for two people,1A Japanese encephalitis vaccine workshop,1vaccine filling workshop and1Vaccine Diluent Workshop. The annual production capacity of rabies vaccine for human use is100010,000 copies, the annual production capacity of Japanese encephalitis vaccine is.1000Ten thousand. All workshops have passed the national new editionGMPCertification.2014Year12Month31On the same day, the company was officially listed in the national small and medium-sized enterprise share transfer system.

　　win honor for the country

The world's leading technical level

Japanese encephalitis is a serious threat to the health of children in China, vaccination is the most economical and effective means of prevention. Chengda Bio has developed an inactivated Japanese encephalitis vaccine with independent intellectual property rights, and its safety indicators are world-leading. into large creatures through“digestion, absorption, innovation”More high-quality vaccines such as human encephalitis vaccine, epidemic hemorrhagic fever vaccine and influenza vaccine have been developed.

The research results of Chengda Biology put an end to the history of the single use of the rotary bottle process for the production of cell culture vaccines in China, and realized the modernization of the domestic vaccine preparation process, the scale of production and the internationalization of quality.

As a high-tech enterprise with extremely demanding environmental requirements, Chengda Biology“Hiding.”In a seemingly inconspicuous Liuyin path in Hunnan District, but as the company's business has entered an explosive period, the company's product research and development, production, and sales are booming, and international merchants have come in droves to paint the Chinese biopharmaceutical market in adversity. A touch of color.2013year,2014year,2015In the year, the company's sales revenue was8.5Billions of dollars,9.37Billions of dollars,9.43100 million yuan, the income and profit in the domestic vaccine industry is second only to Zhongsheng Group, ranking second in the country; it ranks first among the top 100 tax-paying enterprises in Shenyang.54position,51position,50Bit.

All production workshops of the company have passed the new national versionGMPCertification. From2007Since 2010, the company's Chengda human rabies vaccine has maintained the first market share among similar products in China,2011The annual market share is reached.60%More than 20 countries and regions have been exported to India, Pakistan, Thailand, the Philippines and so on. The company's Japanese encephalitis vaccine ranks first in the domestic market share of Class II Japanese encephalitis vaccine. It has been registered in Thailand and Cambodia, and the registration in India is being processed.

　　Innovation-driven

Enter the two major international and domestic markets

　　2016Year8In January, with the proposal of Hunnan District“To create a new highland for the national high-tech industry”Hunnan District has taken a solid step towards building a national independent innovation demonstration zone. Hunnan District proposed that it is necessary to further optimize and strengthen the biomedical industry and build an internationally competitive health and medical industry base.

In the new starting line, into the big creatures to seek new breakthroughs. Based on the company's core technology platform, the company's self-developed bivalent hemorrhagic fever vaccine (VeroCells) have completed clinical work and are applying to the state for production approval.2015The construction of a haemorrhagic fever vaccine production workshop in Shenyang began in the year, and the products will be marketed after passing the national certification.

Innovation-driven, up and down. In the next few years, Chengda Bio will, on the one hand, speed up the expansion of product lines, supplement conventional vaccine varieties at a high starting point, and actively promote the research and development of polyvalent vaccines and innovative vaccines around the national vaccine supply system plan. The company is developing influenza vaccine, chicken pox vaccine, hepatitis A vaccine, etc. are in an orderly progress. The company has invested3000Ten thousand yuan, in Beijing Yizhuang construction of bacterial vaccine research and development center, research and development center in.2014Year6The first vaccine product to be developed is the meningococcal vaccine, which will be developed in succession.23Bacterial vaccines such as pneumonia vaccines. At that time, the company will complete the virus vaccine.(TRUEcells, diploid cells and chick embryo cells)The construction of technology platform and bacterial vaccine technology platform has become one of the most complete vaccine research and development and production enterprises in China.

　　An industry-leading, world-renowned corporate blueprint is becoming a reality. Chengda Creatures Insist“integrity and responsibility”values, continue to build brand awareness in both domestic and international markets, adhere to“International level, domestic leading”Product positioning, and strive to become the industry trustworthy, respected, have important influence of enterprises.

Fu Songyan, Lin Kuan/Text

(From Shenyang Daily 2016Year8Month10Day SectionA02Version)